Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2007
08/16/2007WO2007074491B1 HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
08/16/2007WO2007074472A3 Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
08/16/2007WO2007074291A3 Incontinence treatment methods
08/16/2007WO2007072497A3 Stabilized pharmaceutical composition of pramipexole and method of preparation thereof
08/16/2007WO2007072017A3 Enzyme inhibitors
08/16/2007WO2007071860A3 Compositions including at least one retinoid compound and at least one anti-irritant compound and uses thereof
08/16/2007WO2007071442A3 Inhibitors of ccr9 activity
08/16/2007WO2007070547A3 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
08/16/2007WO2007070546A3 Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects
08/16/2007WO2007068948A3 Pharmaceutical sustained release compositions comprising in particular thyroid hormones
08/16/2007WO2007068073A3 Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine
08/16/2007WO2007067506A3 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
08/16/2007WO2007066130A3 Veterinary composition against endoparasites
08/16/2007WO2007065594A3 Unsaturated fatty acids as thrombin inhibitors
08/16/2007WO2007065261B1 Plasminogen activator inhibitor-1 inhibitors
08/16/2007WO2007064954A3 Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
08/16/2007WO2007064719A3 Formulations of quinolinones
08/16/2007WO2007061882A3 Pyrrolotriazine kinase inhibitors
08/16/2007WO2007060108A3 Aerosol formulation for inhalation containing an anticholinergic agent
08/16/2007WO2007060104A3 Aerosol formulation for inhalation containing an anticholinergic agent
08/16/2007WO2007057598A3 Pharmaceutical or cosmetic composition and a mixed solubilisation method for the production thereof
08/16/2007WO2007056580A3 Methods and compositions for treating diseases associated with pathogenic proteins
08/16/2007WO2007054911A3 Compositions useful for recovering original trophism and pigmentation, and for stimulating growth of the integumentary apparatus, uses and products thereof .
08/16/2007WO2007048843A3 Imidazo-pyridine containing beta agonists, method for producing them and their use as drugs
08/16/2007WO2007042262A3 Ophthalmic emulsions containing prostaglandins
08/16/2007WO2007026959A3 Derivatives of 4-piperazin-1-yl-4-benz0 [b] thiophene suitable for the treatment of cns disorders
08/16/2007WO2007025764A3 Pharmaceutical formulations for salts of monobasic acids comprising clopidogrel
08/16/2007WO2007025229A3 Compositions and their uses directed to hsp27
08/16/2007WO2007019397A3 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus
08/16/2007WO2007016388A3 Liquid formulations for controlled delivery of benzisoxazole derivatives
08/16/2007WO2007016208A3 1,2-benzisoxazole-3-methane-sulfonic acid ammonium salt
08/16/2007WO2007016099A3 Protection of transplanted stem cells with hmg-coa reductase inhibitors
08/16/2007WO2007014671A3 Combinations containing ikk-beta inhibitors
08/16/2007WO2007012841A3 Compositions comprising monobutyrin
08/16/2007WO2007009589A3 Use of soluble guanylate cyclase for the treatment of raynaud's phenomenon
08/16/2007WO2007008562A3 Carbamate compounds for use in treating neurodegenerative disorders
08/16/2007WO2007007919A3 Heterocyclic janus kinase 3 inhibitors
08/16/2007WO2006124753A3 Antipyretic agents against vr1-antagonist-induced increases in body temperature
08/16/2007WO2006121684A3 Acyl hydrazones for treating cardiovascular diseases
08/16/2007WO2006116556A3 Composition comprising proton pump inhibitor and buffer
08/16/2007WO2006116526A8 Polymorph form ii of tanaproget
08/16/2007WO2006115509A3 Small molecule immunopotentiators and assays for their detection
08/16/2007WO2006110580A3 Methods for treating anxiety related disorders
08/16/2007WO2006103449A3 Saminopyrimidine derivates with tie2 inhibiting activity
08/16/2007WO2006093784A3 Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents
08/16/2007WO2006084688A8 HIV protease inhibitors
08/16/2007WO2006079637A8 Heterocyclic tetracyclic tetrahydrofuran derivatives as 5ht2 inhibitors in the treatment of cns disorders
08/16/2007WO2006055660A3 Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
08/16/2007WO2006052555A8 Niacin receptor agonists, compositions containing such compounds and methods of treatment
08/16/2007WO2006052134A3 Food composition comprising a protein- and a lipid fraction for rapidly attenuating inflammatory responses
08/16/2007WO2006047728A3 Bmp gene and fusion protein
08/16/2007WO2006020557A3 Methods of using or identifying agents that inhibit cancer growth
08/16/2007WO2006017590A3 Use of methyl pyruvate for the purpose of reducing weight gain in mammals
08/16/2007WO2005037260A3 Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms
08/16/2007WO2005027835A3 Therapeutic immunization of hiv-infected individuals
08/16/2007WO2005012490A3 Neuroprotective effects of atf6
08/16/2007WO2004103283A3 Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
08/16/2007WO2004091609A3 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
08/16/2007WO2004089294A3 Compositions, methods and kits relating to her-2 cleavage
08/16/2007WO2004071461A3 Tra16 a tr4/tr2 repressor
08/16/2007WO2004060302A3 Methods and compositions for the diagnosis, prognosis, and treatment of cancer
08/16/2007WO2004009029A3 Compositions and methods for treating and preventing infection
08/16/2007WO2004007437A9 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments
08/16/2007WO2003087339A3 Spray freeze dry of compositions for pulmonary administration
08/16/2007WO2003031404A3 Processes for the preparation of substituted isoxazoles and 2-isoxazolines
08/16/2007WO2002083916A8 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
08/16/2007US20070191917 Methods and compositions for treating conditions of the eye
08/16/2007US20070191822 Method and apparatus for acne prevention
08/16/2007US20070191603 Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors
08/16/2007US20070191600 for production of molecular memory devices, solar cells and light harvesting arrays
08/16/2007US20070191599 Methods of manufacturing cortiscosteroid solutions
08/16/2007US20070191495 Lipase inhibitor
08/16/2007US20070191493 Use of n-alkanols as activators of the cftr channel
08/16/2007US20070191492 Method for suppressing lung tumorigenesis
08/16/2007US20070191490 Withacnistin compounds for treatment of cancer
08/16/2007US20070191489 Inorganic acid salts of sibutramine
08/16/2007US20070191488 Method for the treatment of a ubiquitin conjugating disorder
08/16/2007US20070191487 Galenic formulations of organic compounds
08/16/2007US20070191486 thiocolchicine dimers with thiocolchicine residues are liked through a linear aliphatic amido or amido-ureido bridge; antiproliferative, antiinflammatory, antiarthritic, antiviral; enhanced cytotoxicity; 3,5-Benzenedicarboxylic acid bis-(N-deacetylthiocolchicine) amide
08/16/2007US20070191485 Active oxygen scavenging composition including citrulline
08/16/2007US20070191484 Medicaments containing pantothenic acid
08/16/2007US20070191483 Dogs, horses, rabbits, pigs and ruminants (especially beef and dairy cows); feeding starting at or prior to calving, and continued after parturition; increased maintenance of pregnancy, embryonic survival, and likelihood of pregnancy; shorter interval between parturition and first ovulation
08/16/2007US20070191482 treating and preventing pathological states of obesity and related disorders, and a method of treating depression, Parkinson's disease, insulin-independent diabetes mellitus or epilepsy
08/16/2007US20070191481 Sulphonic acid salt of sibutramine
08/16/2007US20070191479 Aniline derivatives as selective androgen receptor modulators
08/16/2007US20070191478 Methods of treating cardio pulmonary diseases with NO group compounds
08/16/2007US20070191477 Schisandrin b preparation
08/16/2007US20070191476 Antioxidant Components for Reduction of Nucleic Acid Damage in Companion Animals
08/16/2007US20070191475 Antimalarial agents; multidrug-resistant malaria; e.g. [3-(1-Phenyl-vinyl)-1,2,5-trioxa-spiro[5.5]undec-9-ylidene]-acetic acid ethyl ester
08/16/2007US20070191474 Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
08/16/2007US20070191473 Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
08/16/2007US20070191472 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
08/16/2007US20070191471 DNT-fumarate and methods of preparation thereof
08/16/2007US20070191470 administering to the patient a compound selected from rotigotine, a physiologically acceptable salt of rotigotine, and a rotigotine prodrug, wherein the compound is administered to provide a rotigotine dosage of 0.05 mg to approximately 50 mg per day
08/16/2007US20070191469 Novel tetracyclic tetrahydrofuran derivatives
08/16/2007US20070191468 Amino alcohol compound
08/16/2007US20070191467 Statin and omega-3 fatty acids for lipid therapy
08/16/2007US20070191466 Metabolites of wortmannin analogs and methods of using the same
08/16/2007US20070191465 Channel blocking compounds
08/16/2007US20070191464 by isomerizing in a mixed solvent of water, salicylaldehyde, and ethanol, crystallization to obtain the stereospecific configuration; high strength sweetener, industrial scale production